title: High mortality rate of (NZW x BXSB)F1 mice induced by administration of lipopolysaccharide attributes to high production of tumour necrosis factor-alpha by increased numbers of dendritic cells.
abstract: (NZW x BXSB)F1 mice (W/BF1 mice) have been reported to be a type of autoimmune-prone mice, showing symptoms of proteinuria, anti-DNA antibodies and anti-platelet antibodies. In this paper, we report that W/BF1 mice show hyperproduction of tumour necrosis factor (TNF)-alpha, responding to lipopolysaccharide (LPS) in comparison with normal mice, resulting in induction of death. In normal mice, monocytes/macrophages (Mo/MØ) are the main producer of TNF-alpha, while both Mo/MØ and dendritic cells (DCs) produce TNF-alpha in W/BF1 mice. Because the number of DCs is higher in W/BF1 mice, the main producers of TNF-alpha in W/BF1 mice are thought to be DCs. Moreover, administration of anti-TNF-alpha antibodies rescued the W/BF1 mice from death induced by LPS, suggesting that TNF-alpha is crucial for the effect of LPS. Although there is no significant difference in the expression of Toll-like receptor-4 (TLR-4) on DCs between B6 and W/BF1 mice, nuclear factor kappa b activity of DCs from W/BF1 mice is augmented under stimulation of LPS in comparison with that of normal mice. These results suggest that the signal transduction from TLR-4 is augmented in W/BF1 mice in comparison with normal mice, resulting in the hyperproduction of TNF-alpha and reduced survival rate. The results also suggest that not only the quantity of endotoxin, but also the host conditions, the facility to translate signal from TLR, and so on, could reflect the degree of bacterial infections and prognosis.
authors.affiliation: First Department of Pathology, Kansai Medical University, Moriguchi City, Osaka, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Koike-Kiriyama
authors.forename: Y
authors.initials: Y
authors.lastname: Adachi
authors.forename: M
authors.initials: M
authors.lastname: Iwasaki
authors.forename: Y
authors.initials: Y
authors.lastname: Amou
authors.forename: A
authors.initials: A
authors.lastname: Shigematsu
authors.forename: Y
authors.initials: Y
authors.lastname: Koike
authors.forename: K
authors.initials: K
authors.lastname: Minamino
authors.forename: H
authors.initials: H
authors.lastname: Mukaide
authors.forename: M
authors.initials: M
authors.lastname: Shi
authors.forename: S
authors.initials: S
authors.lastname: Yanai
authors.forename: M
authors.initials: M
authors.lastname: Matsumura
authors.forename: S
authors.initials: S
authors.lastname: Ikehara
mesh_terms: D000818:Animals; D001327:Autoimmune Diseases / Q000276:immunology*; D003713:Dendritic Cells / Q000276:immunology*; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D008070:Lipopolysaccharides / Q000276:immunology / Q000633:toxicity*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D015398:Signal Transduction / Q000276:immunology; D013154:Spleen / Q000276:immunology; D016019:Survival Analysis; D051197:Toll-Like Receptor 4 / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis* / Q000276:immunology
chemical_list: D008070:Lipopolysaccharides; C493487:Tlr4 protein, mouse; D051197:Toll-Like Receptor 4; D014409:Tumor Necrosis Factor-alpha
references.citation: Nat Rev Immunol. 2003 Feb;3(2):169-76
references.pmid: 12563300
references.citation: J Autoimmun. 2003 Nov;21(3):277-81
references.pmid: 14599853
references.citation: Blood. 2002 Oct 15;100(8):2852-7
references.pmid: 12351395
references.citation: Clin Exp Rheumatol. 1999 Sep-Oct;17(5):539-45
references.pmid: 10544836
references.citation: Immunobiology. 1993 Aug;188(4-5):340-54
references.pmid: 8244442
references.citation: J Immunol. 2000 Nov 15;165(10):5392-6
references.pmid: 11067888
references.citation: Cell. 2002 Jul 26;110(2):191-202
references.pmid: 12150927
references.citation: Clin Rheumatol. 2004 Jun;23(3):235-8
references.pmid: 15168152
references.citation: JAMA. 1996 Aug 21;276(7):565-6
references.pmid: 8709407
references.citation: J Immunol. 2000 Apr 1;164(7):3471-5
references.pmid: 10725698
references.citation: J Immunol. 1999 Apr 1;162(7):3749-52
references.pmid: 10201887
references.citation: Adv Immunol. 1979;28:293-450
references.pmid: 396770
references.citation: Annu Rev Immunol. 2002;20:197-216
references.pmid: 11861602
references.citation: J Exp Med. 1999 Jun 7;189(11):1777-82
references.pmid: 10359581
references.citation: Immunobiology. 1995 Feb;192(3-4):218-30
references.pmid: 7782096
references.citation: Arthritis Rheum. 1983 Nov;26(11):1340-5
references.pmid: 6639692
references.citation: J Exp Med. 1981 Jul 1;154(1):216-21
references.pmid: 7252427
references.citation: J Immunol. 2006 Jan 1;176(1):380-9
references.pmid: 16365431
references.citation: J Immunol. 2001 Nov 1;167(9):5067-76
references.pmid: 11673516
references.citation: Int J Oncol. 1999 Dec;15(6):1191-6
references.pmid: 10568827
references.citation: Immunol Today. 1994 Feb;15(2):74-80
references.pmid: 7512342
references.citation: Stem Cells. 2002;20(1):61-72
references.pmid: 11796923
references.citation: Curr Biol. 2002 Mar 19;12(6):467-71
references.pmid: 11909531
references.citation: Nature. 1992 Mar 26;356(6367):314-7
references.pmid: 1372394
references.citation: Immunity. 2002 Nov;17(5):677-87
references.pmid: 12433373
references.citation: J Exp Med. 1988 Jun 1;167(6):2017-22
references.pmid: 3290385